Silver Spring, Maryland–(ENEWSPF)–February 3, 2015. The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer.
FDA Approves Ibrance for Postmenopausal Women with Advanced Breast Cancer
More in Health and Fitness:
